Correction: Total number of voting rights and size of share capital as of 31 July 2008 after reduction of the share capital of H. Lundbeck A/S

On 22 April 2008, the Annual General Meeting of H. Lundbeck A/S
resolved to reduce the company's share capital by a nominal amount of
DKK 51,966,745 by reducing the company's holding of treasury shares.

The resolution was announced in the electronic information system of
the Danish Commerce and Companies Agency on 28 April 2008, and the
statutory notice period has now expired with no claims received.

Accordingly, the reduction of the company's share capital was
registered with the Danish Commerce and Companies Agency today.

Following the reduction of capital, the nominal share capital of H.
Lundbeck A/S as of 31 August 2008 amounts to 984,431,410 divided into
196,886,282 shares of DKK 5 each and 196,886,282 votes.

The content of this release will have no influence on the Lundbeck
Group's financial result for 2008.

Lundbeck contacts


Investors:                 Media:

Jacob Tolstrup             Jens Harder Højbjerg
Director                   Media Relations Manager
+45 36 43 30 79            +45 36 43 28 33

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


Release No 350 - 31 July 2008

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of
pharmaceuticals for the treatment of psychiatric and neurological
disorders. In 2007, the company's revenue was DKK 11 billion
(approximately EUR 1.6 billion or USD 2.0 billion). The number of
employees is approx. 5,300 globally. For more information, please
visit www.lundbeck.com.